|
Lucky Picks of The Day: (OTCBB:ENMGF)- (OTCBB:MOBS)- (OTCBB:NNVC)
(M2 PressWIRE Via Acquire Media NewsEdge) Rochester NY -- www.shamrockstocks.com names (OTCBB:ENMGF) Entourage Mining Ltd., (OTCBB:MOBS) Mobiform Software Inc., and (OTCBB:NNVC) NanoViricides, Inc. it's "Lucky Picks of the Day!"
To feature your publicly traded company in our alers email us at info@shamrockstocks.com.
Also, you can receive up to the minute stock alerts via our Twitter page. www.twitter.com/shamrockstocks
----------------------------------------------------------------------------------------------------------------------------------------------------------------------
Visit: www.shamrockstocks.com
About Entourage Mining Ltd.
Entourage Mining is a Vancouver based mining exploration company. Currently the Company has two exploration projects: An option to acquire a 100% interest in the Pires Gold Project situated in Goiàs State, Central Brazil and an unencumbered 65% interest in the Doran Uranium Project situated in Costebelle Township, Quebec.
News Today:
VANCOUVER, British Columbia, Jun 1, 2010 -- Entourage Mining Ltd. ("Entourage" or the "Company") (OTCBB:ENMGF) reports that continued surface sampling on the Pires Gold Property in Goais State Brazil has yielded 67 gold (Au) bearing samples between 0.56 (.59ppm) and 80.60 grams (80.60ppm) per metric tonne (g/t) Au.
These 67 samples are from 5 separate target areas, out of a total of 209 samples and analyzed by Intertek do Brasil Inspeções Ltda. of Belo Horizonte. The 5 target areas sampled for gold are situated near the north and south end of a mineralized trend extending over 13 km across the property. In these samples, enrichment in gold occurs in quartz veins (or float derived from quartz veins) and is accompanied by enrichment in other metals including copper (Cu), nickel (Ni), iron (Fe), lead (Pb) and zinc (Zn). The three most gold-rich samples from each of these 5 target areas are listed in Table 1. Note that the samples referred to in this news release are surface grab samples that are selective by nature, and thus unlikely to represent average grades on the property.
Table 1: The most gold rich samples from 5 targets on the Pires Property.
Target Sample # Au g/t As ppm Cu ppm Fe % Ni ppm Pb ppm Zn ppm
------------- ----------- ---------- --------- -------- -------- -------- --------- --------
Target B 10-279 30.1 2071 61 >10 139 378 0
Target B 10-286 28.00 3561 156 >10 200 372 304
Target B 10-280 9.75 348 10 3.79 0 489 0
Au-Cu trend 10-348 41.78 1489 137 >10 280 2184 1704
Au-Cu trend 10-362 22.04 1625 53 >10 254 5788 1679
Au-Cu trend 10-349 16.80 1120 391 >10 182 10109 1055
Point 1 10-409 80.60 1960 544 >10 97 1928 671
Point 1 10-249 50.80 1349 507 >10 89 4442 605
Point 1 10-261 39.95 1506 122 >10 198 143 234
Quartz Hill 10-327 0.56 485 153 3.42 0 4847 0
Garimpo 10-413 73.65 1418 221 >10 435 2796 3929
Garimpo 10-417 12.54 613 174 >10 263 10332 796
Garimpo 10-420 2.49 1331 186 >10 189 2312 312
g/t=grams/tonne; ppm=parts per million
Harrison Cookenboo, Ph D, P.Geo and a qualified person as that term is defined in National Instrument 43-101 has reviewed the technical information of this news release and has developed this table. A 43-101 Technical Report on the Pires property is available on the Company website.
The Company is awaiting the fire assay results of four drill holes drilled in the Point 1 area of the property in April-May 2010.
On behalf of the Board
Entourage Mining Ltd.
Gregory Kennedy
President
------------------------------------------------------------------------------------------------------------------------------------------------------
Visit: www.shamrockstocks.com
About Mobiform:
Mobiform specializes in the compelling visualization of real-time data. Mobiform has produced exceptional data visualization solutions for manufacturing, power & utilities, automation, and other fields of business making use of HMI and SCADA software products. Mobiform leverages Silverlight, Windows Presentation Foundation and Windows Azure by Microsoft in the development of its products.
News Today:
CRYSTAL RIVER, FL, Jun 01, 2010--Mobiform Software Inc. (OTCBB: MOBS) today announced that Mobiform's new version of its Status Vision Designer(TM) is compatible with the OPC Foundation's Unified Architecture ("OPC UA"), recently launched as the successor to OPC DA, which has been the industry standard for the last 15 years.
Version 2.3 of Status Vision Designer is compatible with OPC UA as a source of data into the Status Server. This connectivity allows industry to design desktop and Silverlight based visualization and wire it up to real time OPC UA data without the need for DCOM.
Mobiform attended the OPC Interoperability Workshops in San Leandro, California the week of May 19, 2010. Interoperability testing and compatibility was successfully conducted with OPC UA data servers developed by Canary Labs, Iconics, Inductive Automation, Kepware, Matrikon, MSIIndustrie, Software Toolbox and Takebishi. Additional classic OPC compatibility testing was conducted with GE Intelligent Platforms, Siemens, Yokogawa and Emerson.
Allen Ronald DeSerranno, President & CEO, said, "Mobiform is quickly becoming a significant player in HMI (Human Machine Interface) / SCADA (Supervisory Control and Data Acquisition) software technology. The agreements we've signed with some of the larger players in this space validates the accomplishments of our team. Our continued attendance at the OPC Interoperability Workshops and OPC Road Shows further demonstrates our commitment to developing quality HMI visualization solutions. We believe that this will lead to increasing and profitable new business."
"OPC" is open connectivity with open standards. It is a standardized set of interface protocols to permit real time data from a programmable logic controller ("PLC") in industrial automation, such as status and changes in a plant, to communicate to compatible computers which can store, analyze and/or provide graphic visualization of the real time stream of data from the plant or other physical system. The OPC Foundation is dedicated to ensuring interoperability in automation by creating and maintaining open specifications that standardize the communication of acquired process data, alarm and event records, historical data, and batch data to multi-vendor enterprise systems and between production devices.
------------------------------------------------------------------------------------------------------------------------------------------------------
Visit: www.shamrockstocks.com
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide(TM) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
News Today:
WEST HAVEN, Conn., Jun 01, 2010 -- NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company") reports that its anti-Dengue drug candidates demonstrated significant efficacy in the recently completed preliminary cell culture studies. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley (UC Berkeley).
Several of the anti-Dengue nanoviricides(R) demonstrated a dose-dependent inhibition of Dengue virus infectivity in two distinctly different cell culture models of dengue virus infection. These studies employed the serotype dengue virus 2. The Company believes that these nanoviricide drug candidates mimic a common natural host cell receptor by which the four different dengue virus serotypes bind to the body's host cells, thus causing disease. The virus is "fooled" into thinking it has attached to its target cell and instead enters a nanoviricide nanomicelle, it is believed. A nanoviricide would thus stop the spread of the viral infection to new uninfected cells.
The Company believes that a broad-spectrum nanoviricide that is highly effective against all four dengue serotypes is now feasible, based on the current data. Such a drug would circumvent the problems caused by a phenomenon called "Antibody-Dependent-Enhancement" or "ADE".
Dr. Eva Harris is a leading researcher in the field of dengue viruses. Her group has developed a unique animal model for dengue virus infection and disease that effectively emulates the phenomenon seen in humans, called "Antibody-Dependent Enhancement (ADE)" which is thought to lead to the increased incidence of the more severe disease, dengue hemorrhagic fever and dengue shock syndrome. Selected anti-dengue nanoviricides will be tested in preliminary animal studies using this model.
The Company developed a library of chemical ligands that are expected to bind to the dengue virus envelope proteins of several different subtypes of dengue viruses. These ligands were developed using the results of sophisticated, well established, molecular modeling software. A number of candidate nanoviricides that are capable of attacking the dengue virus were created using these ligands. A "nanoviricide" is a chemical substance made by covalently attaching a number of copies of a virus-binding ligand to a base polymeric micelle, that the Company calls TheraCour(R). It is believed that when a nanoviricide binds to a virus particle, the interaction would extend to the binding of a large number of ligands to the virus surface, and the flexible nanomicelle would then engulf the virus, rendering it incapable of infecting a cell.
Dengue virus is a member of the Flaviviridae family of viruses, some of which are often spread by ticks and mosquitoes. Other important viruses in this family include Yellow Fever virus, West Nile virus and Hepatitis C virus. The market for novel treatments for Hepatitis C is estimated to be in the billions of dollars in the US alone.
When a person is exposed to dengue for the first time, the disease usually is not severe. When the same person is later infected by a different dengue serotype, the body produces antibodies against the previous dengue serotype. The new dengue virus uses these antibodies to infect more cells, thus leading to severe dengue disease. Such a secondary infection may lead to dengue hemorrhagic fever or dengue shock syndrome with high fatality rates. The ADE phenomenon has made development of vaccines and antibody therapeutics against Dengue a tremendous challenge. A vaccine works by creating antibodies against the included serotypes.
Currently there are no approved vaccines for the prevention of dengue, nor drugs for treatment of dengue virus infection. The worldwide market size for an effective anti-dengue treatment may be as large as that for Hepatitis C virus treatment, reaching billions of dollars, based on current population exposure data. Dengue, dengue hemorrhagic fever and dengue shock syndrome are emerging as serious global health problems. Dengue is endemic throughout much of the world and now threatens over 3 billion people world-wide or 40% of the world's population. Because of its world-wide distribution, dengue is considered an emerging threat in the United States. Dengue is officially considered a "neglected tropical disease" by the World Health Organization. About 50-100 million people are infected by dengue virus every year. Recently, the government of Cali, Columbia declared a dengue emergency because of the number of dengue infections and deaths. Globalization and climate change along with changes in the ecology of the virus-carrying mosquito are accelerating the spread of the virus. Without proper treatment, DHF fatality rates can exceed 20%. (Source: WHO Dengue and dengue hemorrhagic fever Fact Sheet No. 117, March 2009; http://www.who.int/mediacentre/factsheets/fs117/en/).
About Dr. Eva Harris' Laboratory at the University of California, Berkeley
The Harris Laboratory in the Division of Infectious Diseases in the School of Public Health at the University of California, Berkeley (www.Berkeley.edu) has developed a multidisciplinary approach to study the molecular virology, pathogenesis, and epidemiology of dengue, the most prevalent mosquito-borne viral disease in humans. Their work addresses viral and host factors that modulate disease severity. One major research focus has been the development of a mouse model to study viral tropism and pathogenesis, investigate the immune response to dengue virus infection, and evaluate candidate anti-viral therapeutics. Dr. Harris' field work focuses on laboratory-based and epidemiological studies of dengue in endemic Latin American countries, particularly in Nicaragua, where ongoing projects include clinical and biological studies of severe dengue, a pediatric cohort study of dengue and influenza transmission in Managua, and a project on evidence-based, community-derived interventions for prevention of dengue via control of its mosquito vector.
------------------------------------------------------------------------------------------------------------------------------------------------------
Visit: www.shamrockstocks.com
About Shamrockstocks.com Shamrockstocks.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by Shamrockstocks. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.
For additional information, please contact info@shamrockstocks.com, www.shamrockstocks.com or www.twitter.com/shamrockstocks.
((Comments on this story may be sent to info@m2.com))
(c) 2010 M2 COMMUNICATIONS
[ Back To Homepage ]
|
